U.S. Markets closed

GenVec, Inc. (GNVC)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
7.190.00 (0.00%)
At close: 3:58PM EDT
People also watch
  • Monster MicroCaps Alert to GNVC shareholders - $BLGO in early part of very big move. Shares up 35% in last week getting ready for several major very bullish events in short term:

    1.    CupriDyne Clean industrial odor control sales exploding.  In under 60 days, 3 of the Top 10 Waste Industry Giants have signed Master Supply Agreements with BioLargo and word on street is that CupriDyne works so much better than the competition that it is going to dominate all odor control. There are over 1,000,000 industrial facilities with serious unmet needs for odor control. CupriDyne destined to be multi-billion-dollar product very soon.
    2.    BioLargo Clyra Medical Division ready to file 510k with FDA this month for revolutionary low cost advanced wound care products.  Clyra has figured out how to use iodine as the most powerful known disinfectant ever known against even resistant strains, and make it completely non toxic.  This is a revolutionary product that is also likely to take a big bite out of the 10 billion dollar wound care industry.
    3.    BioLargo’s AOS SYSTEM is the biggest breakthrough in water treatment in history. A commercial beta Prototype is being unveiled and showcased this August at the University of Alberta.  The market is well over $800 Billion for the AOS SYSTEM.

    Monster MicroCaps BLGO 2017YE Price target - $5.00
    Monster MicroCaps BLGO 2018YE Price target - $18.00


    "2017 is a Break-Through Year" - Dennis Calvert's LD Micro Presentation on June 6, 2017
    BioLargo President and CEO Dennis Calvert presented the company's growth strategy at the 7th annual LD Micro Invitational on June 6th, 2017 ...
  • Second🌱marriage🌱is🌱the🌱triumph🌱of🌱hope🌱over🌱experience.🌱http://dataunion.tistory.com/9802

    GenVec NASDAQ $GNVC Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0 In other words, the correlation coefficient of the other stocks
  • Any chance Novartis buyout the 100% rights to CFG166 from XON/GNVC since they cannot kill GNVC with slow death! Any chance they buy it for $100 million since if drug is successful they would have to pay out a lot, lot more ($230 million, plus loyalties).
  • Anyone know how the status of CFG166 (@ Novartis) can be monitored? Are we just out of luck?
  • Swirsky did not do his best to the value for the shareholders. No one will know why and how they came up with 0.297 shares for one XON and 50%/50% division of the prospective funds (if it happens) from Novartis for 3 years after the buyout.
  • Now that we have been screwed by Swirsky and XON ... guess it is over in regards to that. Now Novartis may be ready to play ball if there is any potential with hearing drug and its delivery. Novartis knows XON is not going away anytime soon or never. They may be willing to buy out all the rights to the CGF166 at a price (last prospective payment was to be $230 million). I hope and wishing for $50 mil? $100 mil? $100 mil would bring $13/GNVC share prior to merger.
  • GNVC is currently selling for less than .297 times the price of XON, which is up substantially today. Anyone interested in owning XON would be wise to buy GNVC now, which will also get you rights to any money paid by Novartis in the 36 months after the XON acquisition is completed.

  • There only is one legitimate lawsuit out there if any others are aware of - James Hoose (major GNVC shareholder) has sued GNVC for now basicly hiding and not disclosing fully for the XON buyout. Anyone have any more information on this lawsuit?
    Unbelievable that we are getting less than $10 mil for the company when you subtract out the GNVC cash and physical assets. Like I said I have no trust in Swirsky. I think this is best for GNVC employess and screw the shareholders.
  • Merger is getting closer. Here's a copy of the prospectus I found under XON that has the language, but dates are not shown.



  • I would expect that by early May we should be notified of when the next quarterly results will be posted, and hopefully a webcast. At that time I think we ought to learn the status of the move to XON, or if their is an alternative to doing it.

    The two stocks generally track one another, but occasionally their are divergences in both directions. On occasion you can actually purchase GNVC for less than .297 times the price of XON. Anyone interested in owning XON ought to by GNVC at that time as you'll not only get the XON, you'll gain perhaps $1 a share of GNVC if the Novartis hearing trial goes to Phase 2B within 36 months of the merger date.

  • There’s only one resource out there that has consistently uncovered the best plays from across the markets, check out ExplosiveOTC. www.explosiveotc.com

  • When will GNVC stock convert to XON?
  • Have I missed something. GNVC is currently trading dramatically higher than the .297 times XON's price. Unless GNVC is either renegotiating or dropping the agreement with XON this trading pattern is not making sense.

    I had not seen the Novartis change until I noted it here. If I understand it, are they speaking of just the Phase 1 portion of the trial, the Phase 1/2, which proceeds doing a Phase 2B, or are they speaking of doing the Phase 2B and completing that by June 2019. I don't believe it's the Phase 2B case, as I believe that would require a new IND, but I could be wrong about that.


  • Thanks for the tip, I did some research and found more information about $GNVC on http://yugestocks.com/?s=GNVC Investing trading stocks. Shanahan's law: the length of a meeting rises with the square of the number of people present.

    Yuge Stocks: Trading Stocks and Making Money
    Stock alerts from the Yuge Stocks. Stock trading, making money and always looking for the next big money maker.
  • Has anyone seen the updated CGF166 Trial Information. Novartis confirmed verification March 21, 2017 It has New Trial Completion Date June 2019 with Primary and Secondary End Points.
  • Question : On what date must I own shares to be eligible for the Novartis Milestones and can I just sell the next day since I would be the name on record? The stock is currently out of synch with XON by $0.50...what's up since it has been on par.
  • Found a great no fee daytrading newsletter, vist T0pMarketGaIners.c0m and sign up...so glad I did
  • Is GNVC overvalued at current levels? check out awesomeSTO-CKS, its a pretty reliable service. of course you have to do your own due diligence, but they generally point you in the right direction.
  • Did anyone else see $GNVC report from http://monstastocks.com/?s=GNVC ? It had some interesting information. Trading stocks day trading. In a way

    Monsta Stocks: Trading Stocks and Making Money
    Stock alerts from the Monsta Stocks. Stock trading, making money and always looking for the next big money maker.